The share price of Dr Reddy's Laboratories, which has been hit heavily by regulatory tangles over the past year or so, rose as much as 9 per cent on Friday, following an agreement on patent settlement with the US-based drug maker Vivus on its weight management capsules, Qsymia. The settlement agreement permits Dr Reddy's to sell the generic version of Qsymia on June 1, 2025, or earlier under c...